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Objective: To investigate the propensity of plumbagin to inhibit the three isoforms of
human cytochrome P450 (CYP), i.e., CYP1A2, CYP2C19, and CYP3A4 using human
liver microsomes in vitro.
Methods: Inhibitory effects of plumbagin on the three human CYP isoforms were
investigated using pooled human liver microsomes. Phenacetin O-deethylation, omep-
razole hydroxylation and nifedipine oxidation were used as selective substrates for
CYP1A2, CYP2C19 and CYP3A4 activities, respectively. Concentrations of paraceta-
mol, 5-hydroxyomeprazole, and oxidized nifedipine were determined in microsomal in-
cubation mixture using high-performance liquid chromatography.
Results: Plumbagin showed signiﬁcant inhibitory effects on all CYP isoforms, but with
the most potent activity on CYP2C19-mediated omeprazole hydroxylation. The IC50
(concentration that inhibits enzyme activity by 50%) values of plumbagin and nootkatone
(selective inhibitor) for CYP2C19 were (0.78 ± 0.01) and (27.31 ± 0.66) mM, respec-
tively. The inhibitory activities on CYP1A2-mediated phenacetin O-deethylation and
CYP3A4-mediated nifedipine oxidation were moderate. The IC50 values of plumbagin
and a-naphthoﬂavone (selective inhibitor) for CYP1A2 were (1.39 ± 0.01) and
(0.02 ± 0.36) mM, respectively. The corresponding IC50 values of plumbagin and keto-
conazole (selective inhibitor) for CYP3A4 were (2.37 ± 0.10) and (0.18 ± 0.06) mM,
respectively.
Conclusions: Clinical relevance of the interference of human drug metabolizing en-
zymes should be aware of for further development scheme of plumbagin as antimalarial
drug when used in combination with other antimalarial drugs which are metabolized by
these CYP isoforms.1. Introduction
Malaria is widespread in tropical and subtropical regions.
The resistance of Plasmodium falciparum (P. falciparum) to
ﬁrst-line antimalarial drugs has resulted in resurgence in treat-
ment failures [1]. Since antimalarial drug resistance compromises
the effective treatment of the disease, there is a pressing need for
ongoing drug discovery research that provides effective andaffordable antimalarial agents. Natural products including
medicinal plants may offer cheap alternative treatment
opportunities for malaria patients.
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) is the
major constituent in several plants including those in Plumba-
ginaceae, Droseraceae, Ancestrocladaceae, and Dio-
ncophyllaceae families. It is a yellow naphthoquinone pigment
which occurs in the plant roots [2]. This compound has been
shown to display a wide effect of pharmacological activities
such as activities against malaria, leishmaniasis, chagas
disease, viral infections, and cancers [2–6]. The ethanol extract
of Plumbago indica Linn. was demonstrated promising
antimalarial activity on chloroquine-resistant (K1) and
chloroquine-sensitive (3D7) P. falciparum clones with medianopen access article under the CC BY-NC-ND
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Furthermore, we have recently demonstrated the antimalarial
activity of plumbagin both in vitro and in vivo [8]. The aim of
the present study was to further investigate the propensity of
plumbagin to inhibit the three isoforms of human cytochrome
P450 (CYP), i.e., CYP1A2, CYP2C19 and CYP3A4 using
human liver microsomes in vitro. The CYP enzyme system
plays crucial roles in the metabolism of xenobiotics and
endogenous substances and thus, has a signiﬁcant impact on
the occurrence of drug–drug interactions particularly metabolic
drug interaction [9]. Interference of hepatic drug metabolizing
enzyme(s) of one drug by the co-administered drug may result
in unexpectedly high plasma concentration of the affected drug
and severe adverse effect or toxicity [10].
2. Materials and methods
2.1. Chemicals
The authentic plumbagin (purity 98.2%) was obtained from
Apin chemicals Co. Ltd (OX, UK). Phenacetin, paracetamol,
caffeine, omeprazole, 5-hydroxyomeprazole, nifedipine,
oxidized nifedipine, ketoconazole, nootkatone, a-naphtho-
ﬂavone, and diazepam were purchased from Sigma–Aldrich (St.
Louis, MO, USA). 1, 4-naphthoquinone was purchased from
Wako Pure Chemical Industries, Co. Ltd. (Osaka, Japan). b-
nicotinamide adenine dinucleotide phosphate (reduced form)
tetrasodium salt (NADPH) was purchased from Merck KGaA
(Darmstadt, Germany). Pooled human liver microsomes (from
50 donors) were obtained from Gibco BRL Life Technologies
(Grand Island, NY, USA).
2.2. CYP inhibition
Inhibitory effects of plumbagin on CYP1A2, CYP2C19 and
CYP3A4 activities were investigated in vitro using pooled hu-
man liver microsomes in a total volume of 500 mL of 0.1 M
sodium phosphate buffer (pH 7.4). The concentration range of
each substrate used was approximately equal to its Km
(Michaelis constant) value. Each experiment was repeated four
times.
2.2.1. HPLC system
Analysis of concentrations of each CYP-mediated metabolite
was performed using the validated high-performance liquid
chromatography (HPLC) method. The HPLC system consisted
of TSP HPLC with P4000 solvent delivery system, equipped
with an AS3000 auto sampler, UV1000 detector, SN4000
controller (Thermo Finnigan, San Jose, CA, USA), and Chrome
Quest software (version 4.0). The HPLC column used was a
Thermo Hypersil Gold C-18 reversed phase column
(210 mm × 4.6 mm, 5 mm particle size). Quality control (QC)
samples were run in duplicate in each analytical batch at low,
medium, and high concentrations. Criteria for acceptability were
four out of six of the QC analyses to lie inside (100 ± 15)% of
the nominal values.
2.2.2. Analytical assay validation
The precision of the assay methods based on intraday
repeatability was determined by analyzing ﬁve series concen-
trations of paracetamol, 5-hydroxyomeprazole, or oxidizednifedipine in phosphate buffer. The repeatability between days
was established using the same concentration range of the three
compounds, but the analysis was performed on three consecu-
tive days. Results are expressed as relative standard deviation (%
RSD) of replicate measurements as follow:
% RSD=
Standard deviation
Mean
× 100
The accuracy of the analytical methods was determined by
comparing the measured concentration of paracetamol, 5-
hydroxyomeprazole, and oxidized nifedipine in phosphate
buffer at each concentration level (n = 5) to the true concen-
tration in three replicates within one day and on three consec-
utive days. Accuracy was reported as percentage bias calculated
from the equation: % Bias = [(Measure value − True value)/True
value] × 100.
Sensitivity of the analytical methods was obtained by the
determination the limit of quantiﬁcation (LOQ). The LOQ was
determined based on signal-to-noise approach by comparing
measured signals from samples with known lowest concentra-
tions of the test compounds (paracetamol, 5-hydroxyomeprazole,
and oxidized nifedipine) and by establishing the minimum
concentrations at a typical signal-to-noise ratio is 10:1.
2.2.3. CYP inhibition
The inhibitory effect of plumbagin on CYP1A2-mediated
phenacetin O-deethylation was performed using a-naphtho-
ﬂavone as a selective inhibitor [11]. In brief, the reaction mixture
was pre-incubated (at 37 C, 5 min) with human liver micro-
somes (0.3 mg/mL, 100 mL), 20 mM phenacetin, and plumbagin
(0–10 mM). The reaction was initiated with the addition of 1 mM
NADPH. Following an incubation (at 37 C) for 60 min, the
reaction was stopped by the addition of 500 mL of cold aceto-
nitrile. The internal standard caffeine (500 mM, 50 mL) was
added and the incubation mixture was cooled on ice for 5 min
and centrifuged at 12000 × g for 15 min. The supernatant was
transferred to an autosampling vial and an aliquot of 20 mL was
injected onto the HPLC column. The concentrations of para-
cetamol (metabolite) were measured by HPLC with UV detec-
tion (240 nm) [11]. The gradient mobile phase consisted of a
mixture of (A) acetonitrile and (B) distilled water; the initial
ratio of mobile phase components (A:B) was 90:10 at a ﬂow
rate of 1 mL/min. The calibration curve was plotted using
high ratio of paracetamol to caffeine on the ordinate, and
concentrations of paracetamol (1–50 mM) on the abscissa.
The inhibitory effect of plumbagin on CYP2C19-mediated
omeprazole hydroxylation was performed using nootkatone as
a selective inhibitor [12]. In brief, the reaction mixture was pre-
incubated (at 37 C for 5 min), with human liver microsomes
(0.5 mg/mL, 100 mL), 10 mM omeprazole, and plumbagin (0–
200 mM). The reaction was initiated with the addition of 1 mM
NADPH. Following an incubation (at 37 C for 60 min), the
reaction was stopped by the addition of 500 mL of cold aceto-
nitrile. The internal standard 1,4-naphthoquinone (10 mM,
50 mL) was added and the incubation mixture was cooled on ice
for 5 min and centrifuged at 12000 × g for 15 min. The super-
natant (800 mL) was transferred to an eppendorf tube and
evaporated using speed vacuum concentrator (FTS System,
Stone Ridge, NY, USA).The dried residue was reconstituted with
100 mL of a mixture of acetonitrile and water (50%:50%, v:v)
and 10 mL injected onto the HPLC column. The concentrations
Table 1
Intra- and inter-assay accuracy and precision of the analytical method for
determination of paracetamol (n = 3 for each concentration).
Quantity of
paracetamol
spiked (mM)
Accuracy (% Bias) Precision (% RSD)
Intra-assay Inter-assay Intra-assay Inter-assay
1 −4.63 −9.18 1.32 6.21
5 −8.10 −4.44 6.30 6.28
10 3.17 −1.92 2.85 5.73
25 4.46 3.54 3.01 5.70
50 −1.13 −0.78 0.86 1.23
Table 2
Intra- and inter-assay accuracy and precision of the analytical method for
determination of 5-hydroxyomeprazole (n = 3 for each concentration).
Quantity of
5-hydroxy
omeprazole
spiked (nM)
Accuracy (% Bias) Precision (% RSD)
Intra-assay Inter-assay Intra-assay Inter-assay
40 3.21 3.23 1.46 2.69
200 −5.86 −6.43 2.03 1.80
800 0.89 2.26 3.93 4.64
1600 3.25 3.52 4.63 2.16
2500 4.45 4.06 4.08 6.22
Table 3
Intra- and inter-assay accuracy and precision of the analytical method for
determination of oxidized nifedipine (n = 3 for each concentration).
Quantity
of oxidized
nifedipine
spiked (mM)
Accuracy (% Bias) Precision (% RSD)
Intra-assay Inter-assay Intra-assay Inter-assay
1.0 −0.94 2.38 1.17 7.05
2.5 2.64 5.20 3.60 0.92
5.0 −1.41 −2.73 5.39 3.54
12.5 0.07 −1.19 4.51 3.23
25.0 0.01 0.35 0.93 0.72
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HPLC with UV detection (302 nm) [12]. The gradient mobile
phase consisted of a mixture of (A) acetonitrile and (B)
distilled water; the initial ratio of mobile phase components
(A:B) was 10:90 at a ﬂow rate of 1 mL/min. The calibration
curve was plotted using high ratio of 5-hydroxyomeprazole to
1,4-naphthoquinone on the ordinate, and concentrations of 5-
hydroxyomeprazole (40–2500 nM) on the abscissa.
The inhibitory effect of plumbagin on CYP3A4-mediated
nifedipine oxidation was performed using ketoconazole as a
selective inhibitor [13]. In brief, the reaction mixture was pre-
incubated (at 37 C, 5 min), with human microsomes (0.3 mg/
mL, 100 mL), 40 mM nifedipine, and plumbagin (0–20 mM).
The reaction was initiated with the addition of 1 mM
NADPH. Following an incubation (at 37 C for 40 min), the
reaction was stopped by the addition of 500 mL of cold
acetonitrile. The internal standard diazepam (80 ng/mL,
50 mL) was added and the incubation mixture was cooled on
ice for 5 min and centrifuged at 12000 × g for 15 min. The
supernatant was transferred to an autosampling vial and an
aliquot of 20 mL was injected onto the HPLC column. The
concentrations of oxidized nifedipine (metabolite) were
measured by HPLC with UV detection (270 nm) [13–15]. The
gradient mobile phase consisted of a mixture of (A) methanol
and (B) distilled water; the initial ratio of mobile phase
components (A:B) was 55:45 at a ﬂow rate of 1 mL/min. The
calibration curve was plotted using high ratio of oxidized
nifedipine to diazepam on the ordinate, and concentrations of
oxidized nifedipine (1–25 mM) on the abscissa.
2.3. Data analysis
IC50 (concentrations causing 50% inhibition of enzyme ac-
tivity) values were calculated from a logdose–response curve
plotted using the Calcusyn™ version 1.1 (BioSoft, Cambridge,
UK). Data are presented as mean ± SD of the four experiments.
3. Results
3.1. Analytical assay validation
The analytical methods for determination of paracetamol, 5-
hydroxyomeprazole, and oxidized nifedipine used in the study
was found to be sensitive and accurate. The linearity of all
calibration curves were demonstrated with coefﬁcient (r2) of
greater than 0.995.
CYP1A2-mediated metabolism: The LOQ of paracetamol at
a signal-to-noise ratio 10 was 1 mM. The precision (intra- and
inter-) of analytical method (% RSD) was <6.3% and the ac-
curacy (intra- and inter-) of the method was <±10% (Table 1).
CYP2C19-mediated metabolism: The LOQ of 5-
hydroxyomeprazole at a signal-to-noise ratio 10 was 40 nM.
The precision (intra- and inter-) of analytical method (% RSD)
was <6.22% and the accuracy (intra- and inter-) of the method
was <±7% (Table 2).
CYP3A4-mediated metabolism: The LOQ of oxidized nifed-
ipine at a signal-to-noise ratio 10 was 1 mM. The precision
(intra- and inter-) of analytical method (% RSD) was <7.05% and
the accuracy (intra- and inter-) of themethodwas<±6% (Table 3).3.2. CYPs inhibition
The inhibitory effects of plumbagin and positive controls on
the activities of three major human CYP isoforms, i.e., CYP1A2,
CYP2C19 and CYP3A4 are shown in Figure 1A–C and the IC50
values are presented in Table 4. Plumbagin clearly inhibited
CYP1A2-mediated phenacetin O-deethylation, CYP2C19-
mediated omeprazole hydroxylation and CYP3A4-mediated
nifedipine oxidation in concentration-dependent manners.
Among the three CYP isoforms, the inhibitory activity was most
potent for CYP2C19, of which its potency was about 35-fold of
the selective inhibitor nootkatone (mean IC50 values of 0.78 mM
vs. 27.31 mM). The inhibitory activities on CYP1A2 and
CYP3A4 were moderate (about 13- to 69-fold lower than the
selective inhibitors).
Table 4
IC50 values (mM) of plumbagin and selective inhibitors on CYP1A2-
mediated phenacetin O-deethylation, CYP2C19-mediated omeprazole
hydroxylation, and CYP3A4-mediated nifedipine oxidation (n = 4 for
each experiment).
Compound CYP1A2 CYP2C19 CYP3A4
a-naphthoﬂavone
(selective inhibitor
for CYP1A2)
0.02 ± 0.36 – –
Nootkatone
(selective inhibitor
for CYP2C19)
– 27.31 ± 0.66 –
Ketoconazole
(selective inhibitor
for CYP3A4)
– – 0.18 ± 0.06
Plumbagin 1.39 ± 0.01 0.78 ± 0.01 2.37 ± 0.10
Figure 1. Inhibitory activities of plumbagin and selective inhibitors on (A)
CYP1A2-mediated phenacetin O-deethylation, (B) CYP2C19-mediated
omeprazole hydroxylation, and (C) CYP3A4-mediated nifedipine oxida-
tion (n = 4 for each experiment).
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Interactions between phytochemicals in herbal medicines and
CYP are now well recognized because of their potential clinical
and toxicological implications. These phytochemicals could act
as substrates, inhibitors or inducers of the CYP isoforms, which
can lead to pharmacokinetic interactions with the co-
administered drugs metabolized by the same CYP isoform
[9,16]. Our results provide evidence for the inhibitory effect of
plumbagin on the three major hepatic CYP isoforms, i.e.,
CYP1A2, CYP2C19, and CYP3A4. CYP1A2, CYP2C and
CYP3A are expressed in human liver at approximately 13, 20
and 30% of total CYP, respectively [17]. Speciﬁc inhibitors
recommended by the US FDA were used as reference
compounds for the inhibitory activity on each CYP. For
CYP2C19 however, since there has been no recommended
selective inhibitor, nootakone was used as a reference
compound as its inhibitory activity was shown to be selective
toward CYP2C19 [12]. Certain extent of variations in
inhibitory activities of the selective inhibitors were observed
compared with that previously been reported. The discrepancy
could be due mainly to the choices of substrates used.
Among the three CYP isoforms under investigation, the
inhibitory activity of plumbagin on CYP2C19 was most evident,
with potency of about 35-fold of the selective inhibitor noot-
katone. CYP2C19 is a major metabolizing enzyme of several
clinically important drugs such as proton-pump inhibitors like
omeprazole and lanzoprazole, anti-epileptic-like mephenytoin,
diazepam, antidepressants, the antiplatelet drug clopidogrel, the
antifungal voriconazole and selective serotonin reuptake in-
hibitors like citalopram [18]. Previous investigations in man have
shown that CYP2C19 activity is susceptible to induction by
herbs and natural products, e.g., St John's wort, Ginko biloba,
and the Chinese herbal mixture Yin Zhi Huang [19–21].
Nevertheless, there has been no clear evidence on the
inhibitory effect of herbal remedies on CYP2C19. Although
inhibitory activity on CYP3A4 was moderate (mean
IC50 = 2.37 mM), the clinical relevance of such interaction
should not be overlooked as this CYP isoform is involved in
the metabolism of 50% of all pharmaceuticals [22]. CYP1A2 is
known to play a major role in the metabolism of pre-
carcinogens and inhibitory effect of plumbagin to this CYP
isoform may contribute only minor interaction with the co-
administered drugs [23]. Several other factors are necessary to
be considered for deﬁnitive conclusion on the clinical relevant
metabolic drug interactions. These include comparative
disposition of the individual constituents responsible for
inhibition, as well as the locations of the affected CYP
(intestine, liver, etc.) [24]. Until further clinical investigations
in healthy subjects are conﬁrmed, the potential of this
compound for use in treatment of malaria infection may be
limited.
The study demonstrated the propensity of plumbagin to
interfere with the three human hepatic CYP isoforms, i.e.,
CYP1A2, CYP2C19, and CYP3A4. The inhibitory potency was
highest on CYP2C19. Concurrent administration of plumbagin
(as pure compound or as the extract of Plumbago indica Linn.)
may result in highly toxic plasma concentrations of the co-
administered drugs that are metabolized by these CYP
Wiriyaporn Sumsakul et al./Asian Paciﬁc Journal of Tropical Medicine 2015; 8(11): 914–918918isoforms. Clinical relevance of the interference of human drug
metabolizing enzymes should be aware of for further develop-
ment scheme of plumbagin as antimalarial drug when used co-
administration with other antimalarial drugs which are metabo-
lized by CYP1A2, 2C19 and 3A4, i.e., quinine, meﬂoquine and
chloroquine.
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